Pre-made Ozoralizumab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH), anti-TNFA/TNF;ALB therapeutic antibody, Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ozoralizumab biosimilar, Bispecific Single Domains (VH-VH'-VH), Anti-TNFA/TNF;ALB Antibody: Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-419-1mg	1mg	Inquiry
GMP-Bios-ab-419-10mg	10mg	Inquiry
GMP-Bios-ab-419-100mg	100mg	Inquiry
GMP-Bios-ab-419-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ozoralizumab biosimilar, Bispecific Single Domains (VH-VH'-VH), Anti-TNFA/TNF;ALB Antibody: Anti-DIF/TNF-alpha/TNFSF2/TNLG1F;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody
INN Name	Ozoralizumab
Target	TNF;ALB
Format	Bispecific Single Domains (VH-VH'-VH)
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	na
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	5m2j:D;None
Year Proposed	2011
Year Recommended	2012
Companies	Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical
Conditions Approved	na
Conditions Active	Rheumatoid arthritis
Conditions Discontinued	Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis
Development Tech	Nanobody Technology